Health Care & Life Sciences » Pharmaceuticals | Hybio Pharmaceutical Co. Ltd.

Hybio Pharmaceutical Co. Ltd. | Mutual Funds

Mutual Funds that own Hybio Pharmaceutical Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
13,322,991
2.27%
-4,824,424
5.09%
12/31/2017
5,844,250
0.99%
0
0.14%
12/31/2017
4,134,653
0.7%
0
0.11%
12/31/2017
Caisse de Dépôt & Placement du Québec
3,243,561
0.55%
0
0%
12/31/2017
E Fund Kexiang Equity Fund
3,076,600
0.52%
3,076,600
1.36%
12/31/2017
E Fund Growth Enterprise Index ETF
2,119,591
0.36%
-334,500
0.56%
12/31/2017
2,053,874
0.35%
-665,600
0.52%
12/31/2017
Nanfang CSI 500 ETF
1,990,263
0.34%
-81,200
0.16%
12/31/2017
1,569,500
0.27%
1,569,500
1.45%
12/31/2017
Andra AP Fonden
1,541,993
0.26%
1,541,993
0%
12/31/2016

About Hybio Pharmaceutical Co.

View Profile
Address
4/F, Hybio Biomedical Park Office
Shenzhen Guangdong 518057
China
Employees -
Website http://www.hybio.com.cn
Updated 07/08/2019
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of polypeptide drugs. It offers Desmopressin acetate injection, Thymopentin, Somatostatin, Terlipressin, and Carbetocin for Injection. It focuses on building a digitalized chronic diseases management platform with the combination of drugs, medical instruments, and Internet.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.